There is no routine screening test for vaginal cancer. Unlike cervical cancer, which is caught through regular Pap smears, vaginal cancer is typically found through a combination of pelvic exams, colposcopy, biopsy, and imaging. The CDC states directly that the Pap test does not screen for vaginal or vulvar cancers. Most diagnoses begin when a person reports symptoms like unusual bleeding or discharge, or when a doctor notices something abnormal during a pelvic exam done for other reasons.
The Pelvic Exam: Where Detection Starts
A standard pelvic exam is usually the first step. During the exam, your provider inspects the outer genitals, then inserts a speculum into the vagina to open the vaginal canal and visually check for any changes in the vaginal walls and cervix. They also insert two gloved fingers into the vagina while pressing on your lower abdomen with the other hand to feel for masses or irregularities in the uterus and ovaries.
Your provider may also perform a Pap test and an HPV test during this exam. While the Pap test isn’t designed to detect vaginal cancer specifically, it can occasionally pick up abnormal vaginal cells. An HPV test checks for high-risk strains of human papillomavirus, which are linked to a higher likelihood of developing vaginal cancer. A positive HPV result doesn’t mean you have cancer, but it may prompt closer monitoring.
Colposcopy: A Closer Look at the Vaginal Walls
If anything looks suspicious during the pelvic exam, the next step is usually a colposcopy. This procedure uses a colposcope, a lighted magnifying instrument that stays outside your body at the vaginal opening. It magnifies the surface of the vagina, vulva, and cervix so your provider can see abnormalities invisible to the naked eye.
During the procedure, your provider inserts a speculum, then swabs the vaginal walls and cervix with a vinegar or iodine solution. This is a key step: the solution causes abnormal tissue to change color, making precancerous or cancerous areas stand out against healthy tissue. Your provider then examines the area through the colposcope, looking for irregular patches, unusual blood vessel patterns, or other signs of abnormal cell growth.
Colposcopy itself isn’t painful, though the vinegar solution can cause mild stinging. The whole procedure typically takes 10 to 20 minutes.
Biopsy: Confirming Whether Cells Are Cancerous
A colposcopy alone can’t confirm cancer. If abnormal tissue is visible, your provider will take a biopsy, removing a small sample of tissue to send to a pathology lab. This is often done during the same appointment as the colposcopy.
The most common method is a punch biopsy, which uses a small circular blade (typically 4 to 5 millimeters) to remove a tiny disc of tissue. This size balances getting enough tissue for analysis with minimal discomfort, and the site rarely needs stitches. For smaller lesions, the punch biopsy may actually remove the entire abnormal area in one step. For larger or more complex lesions, your provider may take multiple punch biopsies from different spots or use a scalpel for a larger excisional biopsy.
You don’t need to do anything special to prepare. The procedure can be done even if you’ve had sex recently or have light bleeding. Heavy menstrual flow might be a reason to reschedule. Your provider will typically use a local anesthetic. Afterward, the biopsy site may feel sensitive for 7 to 10 days. Over-the-counter ibuprofen (400 to 600 mg) is generally enough for pain management. If stitches are placed, they dissolve on their own in about two to three weeks. Some providers recommend soaking the area twice daily in warm water to help with healing.
What Happens in the Lab
The tissue sample goes to a pathologist who examines it under a microscope. Results for a straightforward biopsy usually come back in two to three days. Larger or more complex cancer cases can take around five working days. If the pathologist needs additional testing, such as special stains to identify specific cellular markers, add another one to two days.
The pathologist is looking for how deeply abnormal cells extend into the tissue. Precancerous changes are classified into two tiers. Low-grade changes (sometimes called VAIN 1) involve mild cell abnormalities confined to the surface layer. High-grade changes (VAIN 2 or VAIN 3) show more severe abnormalities penetrating deeper into the tissue and carry a higher risk of progressing to invasive cancer. If abnormal cells have broken through the basement membrane, the boundary between surface tissue and deeper layers, the diagnosis shifts from precancer to cancer.
Imaging Tests for Staging
Once a biopsy confirms vaginal cancer, imaging helps determine how far the cancer has spread. This process, called staging, guides treatment decisions.
MRI is particularly useful for pelvic tumors. It can show the exact location and size of the vaginal tumor and reveal whether nearby lymph nodes in the groin are enlarged. CT scans provide similar information about tumor size and shape but are especially helpful for checking whether cancer has spread to other organs. PET scans are not typically used for early-stage vaginal cancer but become valuable in more advanced cases to identify distant areas of spread throughout the body.
Vaginal cancer is staged using the FIGO system, which runs from Stage I (cancer limited to the vaginal wall) through Stage IVB (cancer that has spread to distant organs). The stage is determined by the managing physician based on the combined results of physical examination, biopsy findings, and imaging.
Why Early Detection Is Difficult
Vaginal cancer is rare, and the lack of a dedicated screening test means it often goes undetected until symptoms appear. The most important thing you can do is pay attention to changes like unusual vaginal bleeding (especially after menopause or after sex), persistent discharge, a mass you can feel, or pelvic pain. HPV vaccination reduces the risk of developing vaginal cancer in the first place, and regular pelvic exams give your provider the best chance of catching abnormalities early, even without a formal screening protocol.